As we move through 2026, the industry is undergoing a "Proactive Transformation." This year, the Aspergillosis Treatment Market has achieved a "Vaccine Milestone," with the first experimental "Fungal Vaccine" entering Phase 2 trials for high-risk leukemia patients. This is proving essential for the 2026 "Prevention-First" goal, as it moves the industry from "Reactive Curing" to "Active...